Details of the Drug Combination

General Information of Drug Combination (ID: DCW8OER)

Drug Combination Name
SY-1425 Topetecan
Indication
Disease Entry Status REF
Glioma Investigative [1]
Component Drugs SY-1425   DMH8UF0 Topetecan   DMAE6LK
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SF-539
Zero Interaction Potency (ZIP) Score: 3.91
Bliss Independence Score: 3.47
Loewe Additivity Score: 4.87
LHighest Single Agent (HSA) Score: 6.96

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [3]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCWD7J7 HL-60(TB) Investigative [1]
Childhood T acute lymphoblastic leukemia DCAVXNM CCRF-CEM Investigative [1]
Adenocarcinoma DCL7S6G A549 Investigative [5]
Melanoma DC0HM0C MALME-3M Investigative [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.